PMID- 25293577
OWN - NLM
STAT- MEDLINE
DCOM- 20160621
LR  - 20211021
IS  - 1776-260X (Electronic)
IS  - 1776-2596 (Linking)
VI  - 10
IP  - 3
DP  - 2015 Sep
TI  - Comparison of tyrosine kinase receptors HER2, EGFR, and VEGFR expression in 
      micropapillary urothelial carcinoma with invasive urothelial carcinoma.
PG  - 355-63
LID - 10.1007/s11523-014-0341-x [doi]
AB  - Invasive micropapillary urothelial carcinomas (MPUC) emerge at higher stages and 
      follow a more aggressive course than conventional invasive urothelial carcinomas 
      (UC). Little is known about the target therapies using tyrosine kinase inhibitors 
      in MPUC. This study is to investigate potential effectiveness of tyrosine kinase 
      receptor inhibitors by determining expression of epidermal growth factor receptor 
      (EGFR), human epidermal receptor 2 (HER2), and vascular endothelial growth factor 
      receptor 2 (VEGFR) proteins in MPUC and UC. 16 cases of MPUC and 16 stage-matched 
      UC were identified. Immunohistochemistry for EGFR, HER2, and VEGFR2 and HER2 gene 
      amplification by fluorescence in situ hybridization (FISH) were performed. HER2 
      and EGFR proteins were expressed in MPUC and UC, with significantly higher HER2 
      expression in MPUC (ratio 1.82, p < 0.01). HER2 gene amplification was identified 
      in 4 of 16 MPUC (25 %). Amplification was limited to cases with 3+ HER2 
      expression (100% concordance). EGFR expression in MPUC was slightly higher than 
      UC but not statistically significant (ratio 1.57, p = 0.19). EGFR and HER2 
      coexpression was noted in 75% of MPUC and 37.5% of UC. No VEGFR expression was 
      identified in the urothelium. Strong VEGFR expression was noted in stromal 
      vessels in both MPUC and UC. In conclusion, EGFR and HER2 are potential targets 
      for neoadjuvant chemotherapy in MPUC and UC. There is no direct anti-tumor effect 
      expected for VEGFR inhibitors.
FAU - Li, Jianhong
AU  - Li J
AD  - Department of Pathology and Laboratory Medicine, Warren Alpert Medical School of 
      Brown University, Rhode Island Hospital, 593 Eddy Street, Providence, RI, 02903, 
      USA, jli4@lifespan.org.
FAU - Jackson, Cynthia L
AU  - Jackson CL
FAU - Yang, Dongfang
AU  - Yang D
FAU - Noble, Lelia
AU  - Noble L
FAU - Wheeler, Michael
AU  - Wheeler M
FAU - MacKenzie, Dolores
AU  - MacKenzie D
FAU - Adegun, Temitope
AU  - Adegun T
FAU - Amin, Ali
AU  - Amin A
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20141008
PL  - France
TA  - Target Oncol
JT  - Targeted oncology
JID - 101270595
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Biomarkers, Tumor)
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - EC 2.7.10.1 (KDR protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - EC 2.7.10.1 (Vascular Endothelial Growth Factor Receptor-2)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Agents/chemistry
MH  - Biomarkers, Tumor/metabolism
MH  - Carcinoma, Papillary/genetics/*metabolism
MH  - Cohort Studies
MH  - ErbB Receptors/*metabolism
MH  - Female
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Invasiveness
MH  - Receptor, ErbB-2/*metabolism
MH  - Urinary Bladder Neoplasms/genetics/*metabolism
MH  - Urothelium/metabolism
MH  - Vascular Endothelial Growth Factor Receptor-2/*metabolism
EDAT- 2014/10/09 06:00
MHDA- 2016/06/22 06:00
CRDT- 2014/10/09 06:00
PHST- 2014/05/28 00:00 [received]
PHST- 2014/09/25 00:00 [accepted]
PHST- 2014/10/09 06:00 [entrez]
PHST- 2014/10/09 06:00 [pubmed]
PHST- 2016/06/22 06:00 [medline]
AID - 10.1007/s11523-014-0341-x [doi]
PST - ppublish
SO  - Target Oncol. 2015 Sep;10(3):355-63. doi: 10.1007/s11523-014-0341-x. Epub 2014 
      Oct 8.